Table 1.
Baseline parameters of patients included in the study.
| Parameter | SC | Icatibant | iC1e/K | p | All Patients |
|---|---|---|---|---|---|
| Female/male | 5/5 | 3/7 | 6/4 | 0.39 | 14/16 |
| Age (y) | 48.9 ± 10.5 | 51.6 ± 9.1 | 54.4 ± 14.8 | 0.58 | 51.6 ± 11.5 |
| BMI (kg/m2) | 29.6 ± 7.8 | 30.2 ± 5.1 | 32.3 ± 7.0 | 0.70 | 30.6 ± 6.7 |
| BMI >30 | 4 | 4 | 6 | 0.59 | 14 (46%) |
| BMI >25 <30 | 2 | 4 | 1 | 7 (23%) | |
| Symptoms onset (d) | 8.8 ± 2.7 | 7.8 ± 2.2 | 8.1 ± 2.5 | 0.57 | 8.1 ± 2.5 |
| Body temperature (°C) | 36.3 ± 0.5 | 36.0 ± 1.2 | 36.6 ± 0.6 | 0.41 | 36.4 ± 1.1 |
| >37 °C (n) | 2 | 2 | 2 | 6 | |
| SatO2 (%) | 92.9 ± 3.3 | 90.7 ± 2.7 | 89.8 ± 7.2 | 0.35 | 91.4 ± 4.7 |
| Lung CT score | 17.9 ± 7.8 | 16.0 ± 6.9 | 19.4 ± 6.4 | 0.60 | 17.8 ± 7.3 |
| Systolic blood pressure (mmHg) | 117.4 ± 10.7 | 121.0 ±10.2 | 127.1 ± 26.0 | 0.51 | 124 ± 18 |
| <90 mmHg (n) | 0 | 0 | 1 | 1 | |
| Diastolic blood pressure (mmHg) | 75.5 ± 12.3 | 79.2 ± 10.4 | 75.4 ± 15.9 | 0.91 | 76.7 ± 12.7 |
| <60 mmHg (n) | 0 | 0 | 0 | 0 | |
| White cell count (×109/L) ¥ | 7.78 ± 4.39 | 7.76 ± 4.98 | 7.76 ± 2.78 | 0.99 | 7.76 ± 4.0 |
| <4 × 109/L (n) | 2 | 2 | 1 | 5 (16.7%) | |
| 4–10 × 109/L (n) | 7 | 6 | 7 | 20 (66.7%) | |
| >10 × 109/L (n) | 1 | 2 | 2 | 5 (16.7%) | |
| Lymphocyte count (×109/L) ¥ | 1.08 ± 0.29 | 1.08 ± 0.39 | 1.37 ± 0.48 | 0.45 | 1.18 ± 0.48 |
| <1 × 109/L (n) | 3 | 3 | 3 | 9 | |
| >1 × 109/L (n) | 6 | 6 | 6 | 18 | |
| Platelet count (×109/L) ¥ | 217.6 ± 55.8 | 217.5 ± 123.5 | 229.9 ± 98.2 | 0.97 | 221.7 ± 93.4 |
| <100 × 109/L (n) | 0 | 1 | 0 | 1 | |
| ≥ 100 × 109/L (n) | 10 | 9 | 10 | 29 | |
| Plasma glucose (mg/dL) ¥ | 176.8 ± 94.9 | 158.9 ± 91.8 | 182.4 ± 111.4 | 0.81 | 172.7 ± 96.2 |
| <125 (mg/dL) (n) | 4 | 6 | 3 | 13 | |
| >125 (mg/dL) (n) | 6 | 4 | 7 | 17 | |
| Serum creatinine (mg/dL) ¥ | 0.9 ± 0.3 | 1.2 ± 0.9 | 0.9 ± 0.3 | 0.34 | 1.00 ± 0.61 |
| <1.2 (mg/dL) (n) | 9 | 8 | 9 | 26 | |
| >1.2 (mg/dL) (n) | 1 | 2 | 1 | 4 | |
| AST (U/L) ¥ | 63.0 ± 54.0 | 82.7 ± 88.9 | 37.3 ± 12.7 | 0.13 | 61.8 ± 62.2 |
| <40 (U/L) (n) | 4 | 3 | 4 | 11 | |
| >40 (U/L) (n) | 6 | 7 | 5 | 18 | |
| ALT (U/L) ¥ | 38.6 ± 35 | 76.7 ± 76.4 | 27.6 ± 13 | <0.01 | 48.3 ± 52.7 |
| <40 (U/L) (n) | 7 | 2 | 8 | 17 | |
| ≥ 40 (U/L) (n) | 3 | 8 | 1 | 12 | |
| LDH (U/L) ¥ | 308.7 ± 55.4 | 396.5 ± 135.2 | 376.5 ± 254.7 | 0.91 | 362.2 ± 176.0 |
| <245 (U/L) (n) | 1 | 2 | 2 | 5 | |
| ≥ 245 (U/L) (n) | 7 | 8 | 8 | 23 | |
| CK (U/L) ¥ | 282.7 ± 245.8 | 299.0 ± 359.2 | 123.0 ± 99.9 | 0.24 | 221.0 ± 213.5 |
| <185 (U/L) (n) | 4 | 1 | 5 | 10 | |
| ≥ 185 (U/L) (n) | 3 | 1 | 1 | 4 | |
| C-Reactive Protein (mg/L) ¥ | 123.2 ± 61.8 | 109.0 ± 81.4 | 110.9 ± 86.3 | 0.76 | 117.6 ± 74.3 |
| <10 (mg/L) (n) | 10 | 10 | 9 | 29 | |
| ≥ 10 (mg/L) (n) | 0 | 0 | 0 | 0 |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CK, creatine kinase; iC1e/K, inhibitor of C1 esterase/kallikrein; LDH, lactate dehydrogenase; SC, standard care. One-way ANOVA/¥ non-parametric distribution (Kruskall–Wallis), chi-square test (for all variables in which the expected numbers were too small no significance was calculated).